Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Interest & Investment Income: 2009-2025

Historic Interest & Investment Income for China Pharma Holdings (CPHI) over the last 17 years, with Sep 2025 value amounting to $294.

  • China Pharma Holdings' Interest & Investment Income fell 79.86% to $294 in Q3 2025 from the same period last year, while for Sep 2025 it was $3,125, marking a year-over-year decrease of 60.12%. This contributed to the annual value of $6,641 for FY2024, which is 0.59% up from last year.
  • As of Q3 2025, China Pharma Holdings' Interest & Investment Income stood at $294, which was down 30.33% from $422 recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Interest & Investment Income registered a high of $6,655 during Q1 2022, and its lowest value of $294 during Q3 2025.
  • For the 3-year period, China Pharma Holdings' Interest & Investment Income averaged around $1,367, with its median value being $1,335 (2024).
  • In the last 5 years, China Pharma Holdings' Interest & Investment Income spiked by 1,539.16% in 2022 and then slumped by 85.76% in 2023.
  • China Pharma Holdings' Interest & Investment Income (Quarterly) stood at $1,412 in 2021, then dropped by 28.97% to $1,003 in 2022, then surged by 152.24% to $2,530 in 2023, then tumbled by 47.23% to $1,335 in 2024, then tumbled by 79.86% to $294 in 2025.
  • Its last three reported values are $294 in Q3 2025, $422 for Q2 2025, and $1,074 during Q1 2025.